PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
Keywords: AGC; ATM; ATP; ATR; AZD-8055; Akt; Akt/PKB; BGT226; BKM-120; CAL-101; CCI-779; CLL; COX2; Celecoxib; DNA-PK; Erlotinib; FDA; FRAP1; GDC-0941; GPCRs; MTD; Mcl-1; NHL; Nilotinib; OSI-027; PDK-1; PH; PI-103; PI3K; PI3K INHIBITORS; PIKKs; PKA; PKB; PKC; PX-866; RAD-001; RCC; Rapamycin; Raptor; Rictor; S6Ks; SCCHN; SF-1126; SGK1; SMG-1; Sunitinib; TCN-PM; TRRAP; UCN-01; Vps34; XL-765; angiogenesis; apoptosis; cancer; cancer therapy; cell growth; clinical; eIF; etoposide; immunity; kinases; mTOR; malignancies; metabolism; migration; monotherapy; motility; mutation; perifosine; proliferation; small-molecule inhibitor; transcription; translation; triciribine phosphate; tumors; xenografts
Document Type: Research Article
Publication date: 2010-12-01
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.